One of Hal Barron's top drug prospects at GSK flunks a PhII test for rheumatoid arthritis, flailing in an intensely competitive field
One of GlaxoSmithKline’s $GSK top pipeline candidates has failed a Phase II trial — badly.
The pharma giant reported today that their anti-GM-CSF — GSK3196165, held up as a top drug candidate by new R&D chief Hal Barron in a recent interview — failed the primary endpoint of DAS28(CRP) < 2.6 at Week 24.
GSK did pull out some positive secondaries, but in an intensely competitive field where other players have been touting much better, statistically significant primary goal results, the future of this drug is very much in doubt.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
